Special Issue "Advances in Pharmaceutical Solid Forms"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 30 April 2022.

Special Issue Editor

Dr. Yohann Corvis
E-Mail Website
Guest Editor
School of Pharmacy, Faculté de Santé—Université de Paris, 4, Avenue de l'Observatoire, 75 006 Paris, France
Interests: solid state chemistry; co-crystal science; active pharmaceutical ingredient and excipient stability; polymorphs screening; nanomedicine; drug formulation; physical chemistry of pharmaceutical ingredients; pharmacokinetics; in vitro dissolution studies; nanocrystals; nanoemulsions

Special Issue Information

Dear Colleagues,

Solubility enhancement of poorly water-soluble drugs is a major challenge in the pharmaceutical field since 80% of the marketed drugs are formulated in solid state and more than 70% of the drugs in development exhibit low solubility (BCS class II and IV). Nevertheless, solid dosage forms are widely favored, mainly due to stability issues of the active ingredients.

A broad and comprehensive study of various solid forms of the pharmaceutical matter is needed to enhance their clinical translation with optimized success. Indeed, the most suitable solid forms have to be taken into consideration regarding their stability and bioavailability.

Many matter modification processes in the solid state, such as salts, solid solutions, scalemic mixtures, amorphous, polymorphs, solvatomorphs, nanocrystals, guest-host assemblies, nanocarriers, and cocrystals formation, have been adapted to challenge and improve both drug substance loading capacity and bioavailability. Each system presents its own advantages and drawbacks, depending on the administration route, the therapeutic target, the release rate of the drug, the final product manufacturing, and the cost of production; the objective behind this survey is to enhance the benefice/risk ratio of innovative formulation for adaptative treatments.

Reviews and original articles dealing with the modulation of pharmaceutical solid dosage forms (with organic or inorganic active ingredients) for formulation, storage, and therapeutic effect enhancement are encouraged for publication in this Special Issue of Pharmaceutics.

Dr. Yohann Corvis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • salt formation
  • solvate/hydrate formation
  • size reduction
  • polymorphism
  • amorphisation
  • solid solutions
  • solid suspensions
  • enantiomeric vs. racemic drugs
  • active ingredient: excipient interactions
  • active ingredient: active ingredient interactions

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Eutectic Formation of Naproxen with Some Dicarboxylic Acids
Pharmaceutics 2021, 13(12), 2081; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13122081 - 04 Dec 2021
Viewed by 365
Eutectic formation with additives is one of the established methods to improve the dissolution behaviors of active pharmaceutic ingredients (APIs). The improvement is mainly due to the increase in the surface area for dissolution, which originates from the finely divided micro-domains generated through [...] Read more.
Eutectic formation with additives is one of the established methods to improve the dissolution behaviors of active pharmaceutic ingredients (APIs). The improvement is mainly due to the increase in the surface area for dissolution, which originates from the finely divided micro-domains generated through the phase separation of the miscible liquid components upon solidification. The present study is to identify eutectic-forming additives for naproxen (NPX), a class II API of the biopharmaceutical classification system. A particular aim was to develop a eutectic mixture with NPX at least over 20 wt%, a minimum to be practical for oral delivery. Screening based on the proximity of the solubility parameter values identified dicarboxylic acids (succinic acid, glutaric acid, and suberic acid) as desirable additives for NPX. Binary melting diagrams were constructed to confirm the eutectic compositions, and the eutectic mixture with suberic acid (NPX 55 wt%) was further investigated. The dissolution (at pH 5.0) of the melt crystallized eutectics was enhanced compared to the simple physical mixture of the same compositions and neat NPX, which was attributed to the microscopically observed lamellar structures. The current study should support the systematic investigations of API eutectic mixtures by selecting appropriate eutectic-forming additives. Full article
(This article belongs to the Special Issue Advances in Pharmaceutical Solid Forms)
Show Figures

Figure 1

Back to TopTop